Tin tức & Cập nhật
Xem bài viết Niệu khoa
Xem
Chỉ hiển thị Multimedia

Erdafitinib prevails in bladder cancer with select FGFRalt
22 Jun 2023
bởiAudrey Abella
The oral selective pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib demonstrated a survival advantage over chemotherapy, extending multiple efficacy endpoints in individuals with advanced or metastatic urothelial carcinoma (mUC) with FGFR alterations (FGFRalt) after previous anti-PD-(L)1 treatment, findings from the confirmatory phase III THOR trial have shown.
22 Jun 2023







